Center for Drug Discovery – Siteman Cancer Center
QuikSTART Grant Application
The Center for Drug Discovery (CDD) and the Siteman Cancer Center partnered to establish the QuikSTART Grant program. The $15,000 award is designed to to advance the translation of new discoveries in cancer disease biology into small molecule therapeutics for the benefit of patients. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivo pharmacokinetics, furnishing drug-like molecules for proof-of-conceptin vivopharmacology studies and intellectual property (patent) filing.
Eligibility criteria. Washington University faculty (Assistant professor and above) holding Siteman Cancer Center membership.
Submission deadline & award notification. Submissions occur 3X annually on March 31, July 31, and November 30. Applications may be confidentially evaluated by an external advisory committee. Award decisions are communicated within 4 weeks.
Award term. The funds are available for 1 year from the NOA date. QuikSTART funding may only be used for purchases and services completed within the project period and cannot be used for expenses incurred prior to the award date.
Expectation. The QuikSTART award is viewed as a “hand-up” to generate preliminary data to enable successful following-on funding (e.g., NCI, NIH, private foundation, commercial partnership), publication, and patent filing.
Reporting. Final reports are required upon project completion. Investigators will be surveyed annually for 3 years after the award expires to capture the return on investment (e.g., publications, grant submissions, other outcomes) for the funding program.
Pre-consultation. Applicants are advised to consult with CDD prior to proposal submission.
Application process:
- Download application form here.
- Submit completed application along with a current Biosketch or CV to Ron Dolle.